Literature DB >> 7813442

Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.

R Fåhraeus1, L Palmqvist, A Nerdstedt, S Farzad, L Rymo, S Laín.   

Abstract

The expression of the Epstein-Barr virus LMP1 oncogene is regulated by viral and non-viral factors in a tissue dependent fashion. The virus encoded transcription factor EBNA2 induces its expression in human B-cells. However, this induction also requires the contribution of cellular and/or other viral factors. In nasopharyngeal carcinoma cells and in cells from Hodgkin's lymphoma, LMP1 gene transcription is independent of viral products. Here we show that the effect of a factor binding to a cAMP responsive-like element (CRE) in the LMP1 gene transcription regulatory sequence (LRS) is essential for efficient promoter activity in the DG75 B-cell line and that elevation of cAMP levels in the cells induces LRS-derived CAT activity in a CRE dependent fashion. Incubation of two EBV-immortalized B-cell lines expressing endogenous EBNA2A with 8-Br cAMP increased the levels of the latency associated 66 kDa LMP1 within 2 h. Interestingly, LMP1 expression in DG75 cells conferred resistance to the inhibitory effect of 8-Br cAMP on cell proliferation. The protein phosphatase 1 and 2A (PP1 and PP2A, respectively) inhibitor okadaic acid also stimulated LRS-CAT activity in DG75 cells. EBNA2A from an EBV-immortalized B-cell line co-immunopurified with a PP1-like protein. An EBNA2A fragment spanning residues 324-436 fused to the GST protein specifically rescued a PP1/PP2A-like component from DG75 cell extracts. This GST-EBNA2A fusion product inhibited a PP1-like activity in nuclear extracts from these cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7813442      PMCID: PMC395581          DOI: 10.1002/j.1460-2075.1994.tb06950.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  79 in total

1.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 2.  Control of transcription factors by signal transduction pathways: the beginning of the end.

Authors:  M Karin; T Smeal
Journal:  Trends Biochem Sci       Date:  1992-10       Impact factor: 13.807

3.  Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences.

Authors:  R Fåhraeus; A Jansson; A Sjöblom; T Nilsson; G Klein; L Rymo
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

Review 4.  Cyclic adenosine 3',5'-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins.

Authors:  T E Meyer; J F Habener
Journal:  Endocr Rev       Date:  1993-06       Impact factor: 19.871

5.  Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells.

Authors:  R Fåhraeus; W Chen; P Trivedi; G Klein; B Obrink
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

6.  Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells.

Authors:  M J Allday; D H Crawford; J A Thomas
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

Review 7.  Epstein-Barr virus and carcinomas.

Authors:  G Niedobitek; H Herbst; L S Young
Journal:  Int J Clin Lab Res       Date:  1993

8.  A general suppressor of RNA polymerase I, II and III mutations in Saccharomyces cerevisiae.

Authors:  S Stettler; N Chiannilkulchai; S Hermann-Le Denmat; D Lalo; F Lacroute; A Sentenac; P Thuriaux
Journal:  Mol Gen Genet       Date:  1993-05

9.  The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.

Authors:  U Zimber-Strobl; E Kremmer; F Grässer; G Marschall; G Laux; G W Bornkamm
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

10.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.

Authors:  E M Deacon; G Pallesen; G Niedobitek; J Crocker; L Brooks; A B Rickinson; L S Young
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  11 in total

1.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

3.  Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins.

Authors:  Innoc Han; Yong Xue; Shizuko Harada; Sigurd Orstavik; Bjorn Skalhegg; Elliott Kieff
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.

Authors:  Horng-Shen Chen; Kayla A Martin; Fang Lu; Lena N Lupey; Joshua M Mueller; Paul M Lieberman; Italo Tempera
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

5.  An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter.

Authors:  A Sjöblom; W Yang; L Palmqvist; A Jansson; L Rymo
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Silencing of the Epstein-Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure.

Authors:  A Sjöblom-Hallén; W Yang; A Jansson; L Rymo
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.

Authors:  Alexey V Gordadze; David Poston; Paul D Ling
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  The effects of the 11 kDa protein and the putative X protein on the p6 promoter activity of Parvovirus B19 in Hela cells.

Authors:  Yanming Dong; Yu Huang; Ying Wang; Peng Xu; Yongbo Yang; Kaiyu Liu; Peter Tijssen; Jianxin Peng; Yi Li
Journal:  Virus Genes       Date:  2012-11-02       Impact factor: 2.332

9.  The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis.

Authors:  Dong Yun Lee; Bill Sugden
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

10.  EBNA3C interacts with Gadd34 and counteracts the unfolded protein response.

Authors:  Jose L Garrido; Seijii Maruo; Kenzo Takada; Adam Rosendorff
Journal:  Virol J       Date:  2009-12-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.